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Abstract
Background: SIN3 (SWI-Independent) is part of a transcriptional deacetylase complex, which
generally mediates the formation of repressive chromatin. The purpose of this work was to study
possible interactions between corepressors human SIN3B (hSIN3B) and the ETO homologues –
ETO (eight twenty-one), MTG16 (myeloid-transforming gene 16) and MTGR1 (MTG-related
protein 1). In addition, the subnuclear localization of the hSIN3B and the ETO homologues was also
examined.
Results: A ubiquitous expression of hSIN3B was observed in adult and fetal tissues. Results with
both ectopically expressed proteins in COS-7 cells and endogeneous proteins in the K562 human
erytholeukemia cell line demonstrated interactions between hSIN3B and ETO or MTG16 but not
MTGR1. Furthermore, nuclear extract of primary placental cells showed complexes between
hSIN3B and ETO. The interaction between hSIN3B and ETO required an intact amino-terminus of
ETO and the NHR2 domain. A nucleolar localization of hSIN3B and all the ETO homologues was
demonstrated upon overexpression in COS-7 cells, and confirmed for the endogeneously
expressed proteins in K562 cells. However, hSIN3B did not colocalize or interact with the
leukemia-associated AML1 -ETO.
Conclusion: Our data from protein-protein interactions and immunolocalization experiments
support that hSIN3B is a potential member of a corepressor complex involving selective ETO
homologues.
Background
Genes are regulated by sequence-specific DNA-binding
transcription factors and interacting partner proteins [1].
These physically interacting partners form complexes that
are responsible for chromatin modifications. The SWI-
Independent (SIN3) [2] (also called SDI1) [3] corepressor
serves as an essential scaffold for several proteins. By
recruitment of histone deacetylases (HDACs), it forms a
deacetylase complex which generally catalyzes the silenc-
ing of the promoter [4-7]. SIN3 can either interact directly
with transcription factors or indirectly through adapter
molecules like NCoR (the nuclear receptor corepressor)
and/or SMRT (silencing mediator of retinoid and thyroid
hormone receptor). The SIN3 homologues have four evo-
lutionarily conserved paired amphipathic helix (PAH)
regions, a histone deacetylase interaction domain (HID)
and a highly conserved region (HCR) [8]. An increasing
number of nuclear proteins have been observed to interact
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with SIN3 in a flexible manner. As a result, SIN3 can both
suppress and activate gene promoters [9].
The SIN3 family consists of SIN3A and SIN3B, which are
highly homologous. Human SIN3B (hSIN3B) contains
1,130 amino acids, which share 90% identity with murine
SIN3B (mSIN3B) [10]. Interactions between murine
SIN3A (mSIN3A) and corepressor proteins such as the
ETO homologues have been reported [11-13]. The ETO
homologues include the transcriptional corepressors ETO
(or MTG8), MTG16 and MTGR1 [14-17]. mSIN3A has
been shown to associate with ETO [11-13], but not with
ETO-2, the murine homologue of MTG16 [11]. Endog-
enously, ETO is known to associate with mSIN3A, N-CoR
and HDACs [12,13]. However, interaction studies
between hSIN3B and the ETO homologues have not yet
been reported.
The ETO homologues are evolutionarily related to the
Drosophila protein Nervy, sharing four conserved
regions: Nervy homology regions (NHR) 1–4 [18]. NHR2
and the flanking regions to NHR2 are required for the
interaction of ETO with mSIN3A [19,20]. The ETO homo-
logues do not bind directly to DNA but rather repress tran-
scription indirectly by binding to nuclear corepressor
proteins such as NCoR, SMRT and mSIN3A [11-
13,21,22]. Obviously, mSIN3A is part of a corepressor
complex that can include ETO as one element. In the
present work, we investigated whether hSIN3B can also
bind to the ETO homologues.
Both ETO and MTG16 are known to carry out transcrip-
tional repression as components of chimeric proteins gen-
erated by chromosomal translocations in certain subtypes
of acute myeloid leukemia (AML). The t(8;21) gives rise to
the AML1-ETO fusion gene [23,24], and the t(16;21) gives
rise to the AML1-MTG16 fusion gene [14]. The leukemia
fusion proteins can recruit corepressors and HDACs, lead-
ing to dysregulated transcriptional repression that is
responsible for a block in cell differentiation [25]. AML1-
ETO retains the DNA-binding region of AML1, but the
transactivation domain is deleted. However, the ETO part-
ner of AML1-ETO retains the conserved regions NHR1-4,
allowing interactions with corepressors. AML1-ETO has
been shown to interact with mSIN3A [12,13].
Additional studies of the interactions between different
isoforms of SIN3 and their partners in the transcriptional
deacetylase complex may provide new knowledge about
gene regulation. Therefore, in the current study we exam-
ined the interactions of hSIN3B with the ETO homo-
logues as well as with AML1-ETO. Our results
demonstrate formation of complexes between hSIN3B
and selective ETO homologues both upon ectopic coex-
pression in COS-7 cells and, more importantly, endogene-
ously in primary placenta cells and the K562 human
erythroleukemia cell line. Furthermore, immunolocaliza-
tion studies showed that hSIN3B and ETO homologues
colocalized to the nucleolus. Our results suggest that
hSIN3B is a member of a corepressor complex involving
specific ETO homologues.
Results
Tissue and cell line expression of hSIN3B and the ETO 
homologues
First, an attempt was made to determine the general
expression of hSIN3B by investigating several tissues.
Results from RT-PCR showed hSIN3B mRNA to be
expressed in all tissues and cell lines examined (Fig. 1A).
Because the transcript levels reach saturation during RT-
PCR, the results may not reflect the true number of tran-
scripts. Therefore, we also carried out real-time PCR,
which showed that hSIN3B and ETO homologues are
ubiquitously expressed with a variable number of tran-
scripts (Fig. 1B–E). The highest expression of hSIN3B was
found in thymus, placenta, pancreas, brain, heart and
lung. In general, these tissues also had the highest expres-
sion of the ETO homologues confirming earlier results
[17]. Furthermore, liver and muscle showed the lowest
transcript levels for both hSIN3B and the ETO homo-
logues. The other tissues showed no covariation between
hSIN3B and ETO homologues.
hSIN3B interacts with selective ETO homologues
ETO has previously been shown to be present in an endo-
geneous complex containing mSIN3A [12]. SIN3 proteins
are large and thus suitable for cooperation with multiple
nuclear partners [9]. For these reasons, we investigated
possible interactions between hSIN3B and ETO homo-
logues. To determine this, transient transfections were car-
ried out in COS-7 cells followed by IP-Western analyses.
Control experiments showed that none of the antibodies
used in these experiments (α-ETO, α-MTGR1, α-MTG16
and  α-SIN3B) bound non-specifically (Fig. 2E). Three
independent experiments were performed and typical
data is shown in Fig. 2. IP was performed with α-ETO and
Western blotting with α-hSIN3B on extracts from cells co-
expressing hSIN3B and ETO. As a result, a protein of
approximately 135 kDa was pulled down, corresponding
to the size of hSIN3B (Fig. 2A, lane 2). Thus, ETO co-pre-
cipitated hSIN3B. The reciprocal IP-Western experiment
demonstrated that hSIN3B co-precipitated ETO as a 75
kDa protein (Fig. 2A, lane 5) further strengthening the
conclusion that hSIN3B and ETO can form a complex. As
hSIN3B interacted with ETO, we also investigated whether
hSIN3B can interact with the chimeric oncoprotein
AML1-ETO. However, hSIN3B was not co-precipitated by
AML1-ETO and in the reverse experiment AML1-ETO was
not co-precipitated by hSIN3B (Fig. 2D, lanes 2 and 5)
indicating a lack of interaction. An interaction was alsoBMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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Tissue expression of hSIN3B and the ETO homologues Figure 1
Tissue expression of hSIN3B and the ETO homologues. (A) Expression of hSIN3B in various tissues and cell lines as 
measured by RT-PCR (Upper panels). Middle panels represent negative controls, wherein RT-PCR was carried out without 
cDNA. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) was used as an endogenous control (Lower panels). (B-E) Tis-
sue expression of hSIN3B and ETO homologues as measured by real-time PCR. Relative transcript levels were calculated after 
normalizing with the G3PDH (see materials and methods). Three independent experiments, each in triplicate were performed 
and error bars show the Standard Deviation (S.D.).BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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shown between hSIN3B and MTG16 (Fig. 2C), but not
between hSIN3B and the ETO homologue MTGR1 (Fig.
2B).
In order to confirm the specificity of these interactions
experiments were also carried out using ETO homologue
constructs tagged with V5 and detected by anti-V5. Three
independent experiments were performed by expression
in COS-7 cells and typical data is shown in Fig. 3. hSIN3B
pulled down ETO-V5 and MTG16-V5 but not MTGR1-V5
(Fig. 3A). In the reverse experiment ETO-V5 and MTG16-
V5 but not MTGR1-V5 pulled hSIN3B (Fig. 3B), Thus, the
results confirmed the specificity of interaction between
SIN3B and ETO homologues; SIN3B interacted with ETO
hSIN3B interacts with ETO homologues, but not with AML1-ETO Figure 2
hSIN3B interacts with ETO homologues, but not with AML1-ETO. COS-7 cells were transfected with ETO (E), 
MTGR1 (R), MTG16 (16) or AML1-ETO (AE) in combination with hSIN3B (S). Cell lysates were analyzed by IP-Western, as 
described in Materials and Methods. IP and Western were performed with α-E (ETO specific), α-R (MTGR1 specific), α-16 
(MTG16 specific) and α-S (hSIN3B specific). (A-C) ETO and MTG16 co-precipitated hSIN3B (lane 2 of A and C). Reciprocal 
experiments showed that hSIN3B co-precipitated ETO and MTG16 (lane 5 of A; lane 6 of C). MTGR1 did not co-precipitate 
hSIN3B or vice-a-versa (lanes 2 and 5 of B). Arrowheads show the position of hSIN3B corresponding to approximately 135 
kDa and ETO corresponding to approximately 75 kDa (lanes 2 and 4). (D) AML1-ETO failed to co-precipitate hSIN3B (lane 2). 
The reciprocal experiment with the same lysates showed that hSIN3B did not precipitate AML1-ETO (lane 5). The size of 
AML1-ETO is about 100 kDa. (E) Control experiments showed that none of the antibodies bound unspecifically. Lower panel 
shows the input of hSIN3B and ETO homologue in 2% of IP lysate. The positions of the molecular weight markers are indicated 
at the left.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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and MTG16 but not with MTGR1. From the present
results, we conclude that hSIN3B can form stable interac-
tions with selective ETO homologues, but not with AML1-
ETO.
We also tried to confirm the interactions between hSIN3B
and ETO homologues in a mammalian two-hybrid assay.
However, a repressor activity of the ETO homologue con-
structs might have lowered the signals making it difficult
to differentiate between interaction of the molecules in
this system (data not shown).
The ETO domain NHR2 and the amino-terminus are 
required for interaction with hSIN3B
Of the four evolutionary conserved regions (NHRs) of
ETO homologues, a region spanning from NHR2 to
NHR4 has been described to associate with corepressors
such as SIN3A, N-CoR and SMRT [11-13,19,20]. Simi-
larly, we wanted to identify the regions of ETO involved in
the interaction with hSIN3B. For this we used ETO
mutants lacking individual NHRs in cotransfection exper-
iments in COS-7 cells. Three independent experiments
were performed and typical results are shown in Fig. 4.
Immunoprecipitation was performed with α-SIN3B fol-
hSIN3B interacts with V5-tagged ETO homologues Figure 3
hSIN3B interacts with V5-tagged ETO homologues. COS-7 cells were transfected with pCMV_ETO-V5 (EV5) pCMV_ 
MTGR1-V5 (ER5), pCMV_ MTG16 -V5 (16V5) in combination with hSIN3B (S) as described in Materials and Methods. IP and 
Western were performed with α-V5 (V5 specific) and α-S (hSIN3B specific). (A-B) ETO and MTG16 co-precipitated hSIN3B 
(Lanes 1 and 7 of A respectively). Reciprocal experiments showed that hSIN3B co-precipitated ETO (Lanes 2 and 8 of B 
respectively). Arrowhead shows the position of ETO in A and MTGR1 in B. MTGR1 failed to co-precipitate hSIN3B (Lane 4 of 
A). The reciprocal experiment showed that hSIN3B did not precipitate MTGR1 (Lane 5 of B). Lower panels in A and B show 
input of hSIN3B and ETO homologue in 2% of IP lysate. The positions of the molecular weight markers are indicated at the left.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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lowed by Western blotting with α-ETO. Deletion of NHR2
abrogated co-precipitation of the ETO mutants by hSIN3B
(Fig. 4A, lane 3). In contrast, deletion of NHR1, NHR3 or
NHR4 did not interfere with the formation of complexes
with hSIN3B (Fig. 4A, lanes 2, 4 and 5). The expression of
hSIN3B was confirmed by performing IP-Western with α-
hSIN3B (Fig. 4B, lanes 2–5), while the expression of ETO
mutants was confirmed by Western blotting with α-ETO
(Fig. 4C).
The ETO part of the leukemia fusion protein AML1-ETO
lacks 30 N-terminal aminoacids. Therefore, it was impor-
tant to determine whether these are important for the
interaction with hSIN3B. Deletion of these amino acids
from the amino terminal region of ETO abrogated co-pre-
cipitation by hSIN3B (Fig. 4D, left panel, lane 4). The
reciprocal experiment showed that this mutant did not co-
precipitate hSIN3B (Fig. 4D, right panel, lane 5). Full
length ETO was used a control to show normal interaction
between hSIN3B and ETO (Fig. 4D, right panel, lane 1 and
Fig. 4D, left panel, lane 2). Importantly, as evident from
our previous result (Fig. 2D), AML1-ETO was unable to
bind to hSIN3B. Our data indicate that both the amino-
terminal part and NHR2 of ETO are required for the inter-
action with hSIN3B.
Endogeneous hSIN3B co-immunoprecipitates ETO
The previous conclusions on interactions between
hSIN3B and ETO homologues are based on data from
overexpression in COS-7 cells (Fig. 2 and 3). Therefore, it
was important to confirm the interactions between endo-
geneous proteins. For this purpose cells from the central
villous part of the placenta were isolated. Results from
Western blotting showed that hSIN3B and all the ETO
homologues are present in the placental cells (Fig. 5A). To
investigate whether ETO homologues were present in
hSIN3B associated nuclear complexes, we immunoprecip-
itated nuclear placental cell extracts with α-SIN3B and
performed Western blotting using ETO homologue spe-
cific antibodies. The reverse experiment was also carried
out. The results show that ETO pulled down a protein of
approximately 135 kDa, corresponding to hSIN3B (Fig.
5B, lane 2), and in the reverse experiment hSIN3B pulled
down a protein of approximately 75 kDa, corresponding
to ETO (Fig. 5B, lane 4). However, no co-immunoprecip-
itation was observed between hSIN3B and MTGR1 or
MTG16 (Fig. 5B, lanes 6 and 8) though input data confirm
the presence of MTGR1 and MTG16 in IP lysates. We were
not able to show input of hSIN3B protein because of a low
protein level in the lysate. Our data show that hSIN3B can
interact with ETO in primary placental cells.
Immunolocalization and antibody specificity
The specificity of the peptide antibodies used against the
ETO homologues in immunoprecipitation and Western
blotting has been shown previously [26]. Furthermore, in
immunolocalization assays using COS-7 cells, antibodies
for hSIN3B (α-SIN3B) and ETO homologues (α-ETO, α-
MTGR1 and α-MTG16) were also shown to bind specifi-
cally to their respective antigens (Fig. 6A, I; 5B, II; 5C, III;
5D, I; and 5E, IV). α-MTG16 showed a faint background
in non-transfected cells, probably due to a low endog-
enous expression of MTG16 in these cells (Fig. 6A–E, III).
However, this antibody produced a strong fluorescence
signal in cells overexpressing MTG16 (Fig. 6C, III). A
quantitative analysis of the DAPI stained cells showed the
transfection efficiency for hSIN3B and ETO homologues
to be 70–80% (Table 1).
Our data confirm that the antibodies to hSIN3B and the
ETO homologues specifically detect their respective anti-
gens in immunofluorescence studies.
Nucleolar localization of hSIN3B and ETO homologues
A punctuate presence of all the ETO homologues in
nuclear particles has been reported [13,27-29], and the
presence of MTG16 in the nucleolus has also been
reported [30]. Nuclear particles are formed at the end of
the cell cycle [31,32] and are thought to migrate towards
the nucleolar organizer region to fuse and aggregate into
nuclear bodies, which eventually form nucleoli. B23 was
used as a marker for nucleolar localization in COS-7 cells.
Three independent experiments were performed and typ-
ical data are shown in Fig. 7. Cells expressing hSIN3B
showed a nucleolar colocalization with B23 (Fig. 7, I).
Moreover, all the ETO homologue transfected individu-
ally showed colocalization with B23 (Fig. 7, II – IV). How-
ever, AML1-ETO was not found in nucleoli but only in
nuclear particles (Fig. 7, V).
A quantitative analysis of the data (Table 2) showed that
80–90 % of successfully transfected cells displayed an
antibody signal in the nucleus only. Nucleoli (B23-posi-
tive) were observed in 11–20% of successfully transfected
cells (% colocalization with B23 plus % no colocalization
with B23 in Table 2). Approximately half of all nucleoli
observed showed a signal for both hSIN3B and the indi-
vidual ETO homologues judging by colocalization with
B23. Thus, our data demonstrate that hSIN3B and the
ETO homologues, but not AML1-ETO, can be targeted to
the nucleolus.
Finally, we examined whether hSIN3B colocalized with
the ETO homologues in the nucleolus. Upon coexpres-
sion of hSIN3B and ETO, we observed colocalization of
both these proteins in nuclear bodies (Fig. 8A, I), the
matrix of the nucleolus (Fig. 8A, II) and at the periphery
of the nucleolus (Fig. 8A, III). The colocalization between
hSIN3B and MTGR1 was not complete (Fig. 7B). Thus, in
some cells MTGR1 was present in nuclear particles (Fig.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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NHR2 and amino terminal domain of ETO are involved in interaction with hSIN3B Figure 4
NHR2 and amino terminal domain of ETO are involved in interaction with hSIN3B. Lysates were prepared from 
COS-7 cells transfected with hSIN3B (S) in combination with ETO (E) and ETO mutants lacking NHR1 (N1), NHR2 (N2), 
NHR3 (N3), NHR4 (N4) or ETO lacking 30 amino-terminal aminoacids (30) as described in Material and Methods. (A) IP was 
performed with α-SIN3B followed by Western blotting with α-ETO (α-E). The ETO mutant lacking NHR2 was not pulled 
down by hSIN3B (lane 3). (B) Both IP and Western blotting with α-SIN3B (α-S) confirmed expression of hSIN3B (arrowhead). 
(C) Western blotting performed with α-E demonstrated expression of all the mutants (arrowhead). (D) IP was performed 
with α-SIN3B or α-ETO followed by Western blotting. The presence in the left panel of ETO in lane 1 but not in lane 4 (lack-
ing 30 amino-terminal aminoacids) showed that the ETO amino-terminus is required for interaction with hSIN3B. Reciprocal 
experiment showed that hSIN3B co-precipitated ETO (right panel, lane 2) but not ETO – 30 aminoacids (right panel, lane 5). 
Arrowheads show the position of ETO, ETO – 30 aas and hSIN3B. Lower left and right panels show input of ETO and hSIN3B 
in 2% of IP lysate. The positions of the molecular weight markers are indicated at the left.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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8B, I) with or without colocalization with hSIN3B at the
periphery of these (Fig. 8B, II–III). Complete colocaliza-
tion was also observed between hSIN3B and MTG16 in
nuclear bodies (Fig. 8C, I), in the nucleolar matrix (Fig.
8C, II) and at the periphery of the nucleolus (Fig. 8C, III).
No nucleolar colocalization was observed between
hSIN3B and AML1-ETO (Fig. 8D) consistent with the lack
of interaction between these proteins in IP-Western exper-
iments (Fig. 2D). A quantitative analysis of the data from
cotransfection of hSIN3B and ETO homologues is shown
in Table 3. A majority of cells showed nuclear colocaliza-
tion (70–78%). Furthermore, significant colocalization
was seen in nuclear bodies, nuclear particles and nucleoli.
No colocalization was observed between hSIN3B and
AML1-ETO.
hSIN3B interacts with ETO in primary placenta cells Figure 5
hSIN3B interacts with ETO in primary placenta cells. (A) Western blotting was used to detect hSIN3B and ETO 
homologues in TRIZOL extract of primary placental cells as described in Material and Methods. The following antibodies were 
used: α-hSIN3B (SIN), α-ETO (ETO), α-MTGR1 (R1), α-MTG16 (16) and α-MTG (MTG, reactive with all ETO homologues). 
Arrowhead shows the position of hSIN3B and ETO homologues. The blots were re-probed with pre-immune serum (PIS) in 
order to rule out non-specific binding of the antibodies. The blots were probed with α-actin to show equal loading. (B) IP-
Western was used to examine the presence of complexes between hSIN3B and the ETO homologues in nuclear extracts. IP 
with α-MTG pulled down hSIN3B as detected on immunoblotting with α-SIN3B (SIN) (lane 2). In the reverse experiment, IP 
with α-SIN3B (SIN) pulled down ETO as detected on immunoblotting with α-ETO (ETO) (lane 4). However, IP with α-SIN3B 
(SIN) did not pull down MTGR1 or MTG16 as no signal was detected upon immunoblotting with α-MTGR1 or MTG16 (lanes 
5–8). Lower panel shows input of MTGR1 and MTG16 in 2% of IP lysate. The positions of the molecular weight markers are 
indicated at the left.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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Nucleolar localization of hSIN3B and ETO homologues in 
K562 cells
We confirmed the nucleolar colocalization between
hSIN3B and ETO homologues observed upon overexpres-
sion in COS-7 cells (Fig. 8) by studies of endogeneous
proteins. The HEL human erythroleukemia cell line is the
only leukemic cell line that we know of that expresses
transcripts for both hSIN3B and all three ETO homo-
logues (this work, [33]), but hSIN3B was not detectable
by immunoblotting in these cells (data not shown).
Therefore, we used the K562 human erythroleukemia cell
line instead although the data will be limited to MTG16
and MTGR1 as this cell line does not express ETO [33]. In
support of this, immunoblotting showed the presence of
hSIN3B, MTGR1 and MTG16 but not ETO (Fig. 9A). A
nucleolar localization of SIN3B, MTGR1 and MTG16 was
Nuclear localization and antibody specificity Figure 6
Nuclear localization and antibody specificity. (A-E) COS-7 cells were transfected with ETO, MTGR1, MTG16, AML1-
ETO or hSIN3B (A to E respectively). Cells were immobilized, lysed and incubated with α-ETO, α-MTGR1, α-MTG16 or α-
SIN3B as described in Materials and Methods. ETO (A I), MTGR1 (B II), MTG16 (C III), AML1-ETO (D I) and hSIN3B (E IV) 
were localized in the nucleus. (F) Untransfected (Untransf.) cells showed no immunofluroscence (I, II and IV) except for a faint 
background with α-MTG16 (III). Size bars (10 μM) are shown in panel AI.
Table 1: Transfection efficiency (%) of hSIN3B and ETO homologues.
Transfection Cells-analyzed α-SIN3B (%) α-ETO (%) α-MTGR1 (%) α-MTG16 (%)
hSIN3B 149 68 0 0 0
ETO 128 0 83 0 0
MTGR1 143 0 0 68 0
M T G 1 6 1 3 8 000 7 4
AML1-ETO 143 0 68 0 0
U n t r a n s f e c t e d 1 0 0 0000
A total of 100 to 150 DAPI stained COS-7 cells successfully transfected with hSIN3B, ETO homologues or AML1-ETO were analyzed after probing 
with the respective antibodies. Untransfected cells did not show antibody binding (last row).BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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observed (Fig. 9B), and hSIN3B was shown to colocalize
with MTGR1 and MTG16 (Fig. 9C). These observations
strengthen our observations that hSIN3B colocalizes with
ETO homologues, MTGR1 and MTG16 in the nucleolus.
Discussion
The major role of SIN3 proteins is to recruit HDACs,
which catalyze deacetylation of histones leading to the
creation of a repressive chromatin structure [4-7,34].
Nucleolar localization of hSIN3B and ETO homologues Figure 7
Nucleolar localization of hSIN3B and ETO homologues. The first column of each panel shows the Nomarski index. 
The second column shows nuclear staining with DAPI. The third column shows the localization of individual proteins. The 
fourth column shows nucleolar localization of the B23 nucleolar marker. The fifth column shows a merge of B23 and individual 
proteins. hSIN3B (I) and all the ETO homologues (II – IV) show colocalization with B23. AML1-ETO lacks colocalization with 
B23 (V). Size bars measuring 10 μM are shown in panel II.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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mSIN3A has been extensively studied as a corepressors,
and is known to interact with ETO homologues [11-
13,19,20,35,36]. The following observations were made
in the present work: (1) The corepressor hSIN3B was
shown to be ubiquitously expressed in human tissues and
cell lines. (2) Upon ectopic expression, hSIN3B was
shown to interact with ETO and MTG16 but not with
MTGR1 or AML1-ETO. (3) In primary placenta cells,
hSIN3B was found to interact with ETO but not with
MTG16 or MTGR1. (4) A nucleolar localization of hSIN3B
and ETO homologues was observed both for overex-
pressed proteins in COS-7 cells and endogenous proteins
in the K562 leukemia cell line. Collectively, the results
suggest that hSIN3B is a member of a chromatin-repressor
complex involving selective ETO homologues.
SIN3A and SIN3B differ in their interactions with ETO 
homologues
The region of ETO involved in binding to mSIN3A has
been mapped to NHR2 and its flanking regions [11,19].
Table 2: Quantitative analysis of nuclear and nucleolar localization of hSIN3B and ETO homologues.
Transfection Cells analyzed Nuclear signal only (%) Nucleolar Signal with B23 (%) Nucleolar signal without B23 (%)
hSIN3B 110 80 10 10
ETO 107 82 7 11
MTGR1 106 84 6 10
MTG16 113 84 12 4
AML1-ETO 415 89 0 11
A total of 106 to 415 DAPI stained cells successfully transfected with hSIN3B, ETO homologues or AML1-ETO were analyzed. B-23 was used as a 
marker for nucleoli. A majority of these cells showed a nuclear signal. Nucleoli were visible in 11–20% of the cells (column 4 plus column 5). The 
ETO homologues showed a nucleolar localization in approximately half of these cells as. AML1-ETO showed no nucleolar localization.
Colocalization of hSIN3B and ETO homologues Figure 8
Colocalization of hSIN3B and ETO homologues. ETO, MTGR1, MTG16 or AML1-ETO (A.E) was cotransfected with 
hSIN3B (SIN) in COS-7 cells and analyzed with immunofluorescence microscopy. (A) ETO and hSIN3B colocalized in nuclear 
bodies (I), in the matrix of the nucleolus (II) and at the periphery of the nucleolus (III). (B) MTGR1 and hSIN3B were observed 
separately in nuclear particles and in nuclear bodies respectively (I), but alternatively both were seen at the periphery of 
nuclear particles (II) or lacked colocalization (III). (C) MTG16 and hSIN3B colocalized in nuclear bodies (I), in the matrix of the 
nucleolus (II) and at the periphery of the nucleolus (III).(D) AML1-ETO was observed in the nucleus only whereas hSIN3B was 
seen in the nucleolus (I – III). Size bars of 10 μM are shown in panel I of part A.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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Our data show that NHR2 is required for an interaction
between hSIN3B and ETO. Beyond this, our results also
show a role for the amino-terminal part of ETO for an
interaction with hSIN3B. This is consistent with the
observed lack of an interaction between hSIN3B and
AML1-ETO, which is devoid of the 30 amino-terminal res-
idues present in wildtype ETO [37]. However, not only the
absence of these residues but also steric hindrance caused
by the AML1 part of the chimeric AML1-ETO protein
could be important for lack of interaction.
Interaction between hSIN3B and selective ETO 
homologues
The corepressor mSIN3A is known to interact with ETO
and MTGR1 [11-13,19,20,35]. In contrast to SIN3A, we
demonstrated interactions between hSIN3B and ETO or
MTG16 but not MTGR1 in COS-7 cells by overexpression.
The results of overexpression studies may not necessarily
reflect protein interactions as they occur normally. Inter-
estingly, an interaction between hSIN3B and ETO was
also detectable in primary cells from the villous part of the
placenta. Therefore, our results suggest a non-redundant
interaction between hSIN3B and ETO homologues.
hSIN3B and all the ETO homologues show nucleolar 
targeting
A nuclear localization of ETO homologues and AML1-
ETO has been reported previously [27-29,38-40]. Further-
more, nucleolar targeting of MTG16 but not of ETO and
MTGR1 has been reported by Hoogeveen et al. [30]. How-
ever, we observed all ETO homologues as well as hSIN3B
to be targeted to the nucleolus upon overexpression in
COS-7 cells (Fig. 6B). There are intrinsic problems associ-
ated with overexpression systems used for these studies
wherein the type of plasmid and the efficiency of transfec-
tion may influence the results. Importantly, we confirmed
the nucleolar colocalization endogenously in the K562
human erytroleukemia cell line.
Possible role of hSIN3B and ETO homologues in 
transcriptional inactivation
The periphery of the nucleolar chromatin ring contains a
large number of inactive methylated rDNA repeats
[41,42]. MTG16 has been demonstrated to be localized at
the nucleolar periphery and suggested to play a role in
rDNA silencing [30]. In addition, we observed ETO as well
as MTGR1 at the nucleolar periphery (Fig. 6, 7). Likewise,
we observed a peripheral nucleolar localization of
hSIN3B. Furthermore, involvement of the SIN3 corepres-
sor complex in rDNA silencing has been reported [43].
The presence of transcriptional repressors like hSIN3B
and ETO homologues in the nucleolus could lead to tran-
scriptional inactivation of rDNA and a slowdown of cell
proliferation [44,45].
Unlike SIN3A, hSIN3B does not interact with AML1-ETO
AML1-ETO is known to suppress AML1-responsive gene
transcription [46]. AML1-ETO has been shown to interact
with mSIN3A [12,13], but our data show that it does not
interact with hSIN3B. This seems to be explained by the
deletion of the amino-terminus of ETO in AML1-ETO as
an aminoterminal deletion of 30 aminoacids abrogated
the interaction between ETO and hSIN3B. Previous [38-
40] and present studies show lack of targeting of AML1-
ETO to the nucleolus. This is in contrast to the nucleolar
targeting of ETO. Furthermore, upon coexpression with
hSIN3B, AML1-ETO and ETO showed separate nuclear
localization (Fig. 7A and 7D). Therefore our data suggest
that AML1-ETO is not a part of a possible hSIN3B-associ-
ated complex.
Conclusion
Taken together, our data indicate that hSIN3B is a poten-
tial member of a core repressor complex involving the
ETO homologues. The NHR2 domain of ETO and its
flanking regions are involved in making contact with the
corepressor mSIN3A [11,19] and our data suggests that
NHR2 and the amino-terminus of ETO are required for
contact with hSIN3B. This difference may be attributed to
the difference in the structure of the PAH2 domain of
SIN3 homologues [47]. We speculate that a corepressor
complex involving ETO homologues may contain either
SIN3A or SIN3B. It is unlikely that both SIN3A and SIN3B
are part of the same complex involving ETO homologues.
Previous studies have shown that ETO pulls down a com-
plex of about 600 kDa that contains mSIN3A, NCoR and
HDACs [12]. A nucleolar repressor complex of this lim-
ited size is unlikely to be able to hold both SIN3A and
SIN3B, as both are large proteins. We propose a model in
which a corepressor complex contains either hSIN3A or
Table 3: Quantitative analysis of the data on colocalization between hSIN3B and ETO homologues.
Transfection Cells analyzed Nuclear colocalization 
(%)
Nucleolar 
colocalization (%)
Nuclear body 
colocalization (%)
Nuclear particle 
colocalization (%)
SIN – ETO 139 70 14 10 6
SIN – MTGR1 131 77 14 4 5
SIN – MTG16 129 78 18 2 2
A total of 108 to 139 DAPI stained COS-7 cells successfully cotransfected with hSIN3B (SIN) and ETO homologues were analyzed. These cells 
were divided into % of cells showing nuclear colocalization, nucleolar colocalization, nuclear body colocalization and nuclear particle colocalization.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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Nucleolar colocalization of hSIN3B and ETO homologues in K562 cells Figure 9
Nucleolar colocalization of hSIN3B and ETO homologues in K562 cells. A. Expression of hSIN3B (SIN3B) and the 
ETO homologues in K562 cells as detected by immunoblotting. The α-MTG antibody reacts with all ETO homologues. B. 
Localization of hSIN3B and ETO homologues in the nucleolus. The first column of each panel shows the Nomarski index. The 
second column shows nuclear staining with DAPI. The third column shows the the B23 nucleolar marker. The fourth column 
shows nucleolar localization of individual proteins. The fifth column shows a merge of B23 and individual protein. hSIN3B (I) 
and the ETO homologues (II), MTGR1 (III) and MTG16 (IV) showed colocalization with the B23. C. Colocalization of hSIN3B 
and MTG16 or MTGR1 in the nucleolus. Columns are designed as in B. Size bars of 10 μM are shown in panel I of part B and C.BMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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hSIN3B, but not both. The ETO homologues of this com-
plex may be interchangeable. Finally, the finding of
hSIN3B as an interacting partner for specific ETO homo-
logues in the nucleolus suggests an epigenetic control of
nucleolar transcriptional regulation.
Methods
Reverse transcription PCR
The expression of hSIN3B in various human tissues and
cell lines was determined by reverse transcription PCR
(RT-PCR). Human fetal and adult multiple-tissue cDNA
(MTC) panels (Clontech Laboratories Inc., Palo Alto, CA,
USA) and cDNA prepared from various hematopoetic cell
lines were used as template. For preparing cDNA from cell
lines, total RNA was extracted from cells using the RNeasy
mini kit (Qiagen, Hilden, Germany). The Omniscript RT
kit (Qiagen, Hilden, Germany) was used for synthesis of
cDNA from one microgram of RNA using random hex-
amer as primer, following the manufacturers' instructions.
PCR parameters were: 32 × (95°C for 30 s, 68°C for 2
min) followed by extension at 68°C for 3 min. The cho-
sen primer sequences unique to hSIN3B were situated on
separate sides of an intron, in order to remove the possi-
ble amplification of genomic DNA. The sequences of the
forward and reverse primer were – 5'-GCCACGA-
GAAGCTGCCGGTGCACGTA-3' and 5'-CACCGTC-
CCCGTGGTTGTGCGAATTCT-3'. Amplification of
G3PDH was used as internal control for all the tissues. All
PCR reactions were done in triplicate from two independ-
ent MTC panels.
Real-time RT-PCR
For real-time RT-PCR of hSIN3B and ETO homologues,
human fetal and adult multiple-tissue cDNA (MTC) pan-
els were used as templates. Taqman Universal PCR Master
mix and 7,000-sequence detection system were used
(Applied Biosystems, CA, USA). Primer and probe con-
centrations were 0.9 μM and 0.25 μM, respectively. PCR
parameters were: 50°C for 2 min, 95°C for 10 min and 40
× (95°C for 15 s and 60°C for 1 min). For hSIN3B, primer
and probe mix were from Applied Biosystems Assay on
demand™ Hs00391562_m1. The real-time RT-PCR for the
ETO homologues was carried out as previously described
[33].
The threshold cycle (Ct) was determined for all samples. A
standard curve was generated by linear regression of the Ct
values from cDNA of the HEL cell line; the corresponding
RNA amounts ranged from 1 pg to 100 ng. The 1 pg stand-
ard was the denominator, set to 1. Based on the Ct values
of the samples, transcript levels were derived from the
standard curve and normalized against the normalizing
standard G3PDH. For statistical comparison between tis-
sues, the transcript level of fetal kidney was kept as 1. The
PCR reactions were done three times, each one in tripli-
cate from MTC panels. Standard deviation was calculated
from the mean of three experiments and plotted as error
bars.
Plasmids
The coding sequence of hSIN3B was amplified from
cDNA in clone fh15187 (KIAA0700 in pBluescript from
Kazusa DNA Research Institute, Japan). Restriction cleav-
age sites were introduced at both ends of the coding
sequence. The PCR products were digested with Mlu1 and
SalI, and cloned into the pCMV5 vector. The coding
sequences of MTGR1a and MTG16a (kind gifts from Dr. F.
Morohoshi) were introduced into pCMV5 as previously
described [33]. pCMV5_ETOb and pCMV5 vectors with
ETO NHR1-4 deletion mutants (pCMV5_ETOΔTAF,
pCMV5_ETOΔHHR, pCMV5_ETOΔNervy and
pCMV5_ETOΔMYND) were kind gifts from Dr. Scott Hie-
bert. The coding sequences of ETO, MTGR1 and MTG16
were also introduced after PCR amplification with V5 tags
into pCMV5 vector (pCMV5_ETO-V5, pCMV5_MTGR1-
V5 and pCMV5_MTG16-V5). A new deletion mutant of
pCMV_ETO lacking the first 30 aas was also constructed
after PCR amplification (pCMV_ETO-30). All the con-
structs were sequenced using Big Dye Terminator cycle
sequencing kit (version 3.1) (Applied Biosystems, CA,
USA).
Cells and transfection
HEL, K562, U937, NB4, THP and HL60 cells were grown
in a 5% CO2 atmosphere at 37°C in RPMI – 10% FBS and
COS-7 cells were grown in DMEM -10% FBS (Gibco BRL,
MD, USA). Cell counting was done in a Burker chamber
and viability was determined by Trypan blue exclusion.
COS-7 cells were transfected using Polyfect (Qiagen,
Hilden, Germany) according to the manufacturer's
instructions. For Western blotting and IP-Western 2.5 ×
106 cells were seeded in a 10 cm2 Petri dish, transfected the
next day with 10 μg of plasmid and analysed 48 h later.
For immunofluorescence staining, 0.4 × 106 COS-7 cells
were seeded in a six-well plate, transfected the next day
with 1.2 μg of plasmid and allowed to grow for another 24
h before analysis. For immunofluorescence staining on
endogenous proteins in K562 cells, 1 × 106 cells per well
were fixed in 96-well plate.
Collection of placental tissue and nuclear extraction
Placental tissue was collected at the Department of
Obstretics and Gynecology, Lund University hospital.
Sampling was performed after informed consent as
approved by the Ethical Committee review Board for stud-
ies of human subjects. Tissue was taken from the central
villous part of the placenta as described [48]. For nuclear
extraction (all steps at 4°C), 150 mg of fresh placental
cells were homogenized 3 times for 10 sec each, withBMC Molecular Biology 2008, 9:8 http://www.biomedcentral.com/1471-2199/9/8
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intermittent cooling in 3 ml of a cell lysis buffer [10 mM
HEPES-KOH (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.1%
NP-40] supplemented with 0.5 mM DTT and 0.2 mM
PMFS. The homogenate was left on ice for 1 h and centri-
fuged at 3,400 × g for 4 min. The cell pellet was extracted
with 1.5 ml of a nuclear lysis buffer [20 mM HEPES-KOH
(pH 7.9), 1.5 mM MgCl2, 0.2 mM EDTA, 420 mM NaCl,
25% Glycerol] supplemented with 0.5 mM DTT and 0.2
mM PMFS. The lysate was kept on ice for 1 h and centri-
fuged at 10,000 × g for 15 min. The nuclear extract thus
obtained was diluted 1:20 in a lysis buffer [250 mM NaCl,
20 mM Na-phosphate (pH 7.0), 30 mM Na-pyrophos-
phate (pH 7.0), 5 mM EDTA, 0.1 mM Na3VO4, 10 mM
NaF, 0.1% NP-40].
IP-Western blotting
Cells were lysed in 250 mM NaCl, 20 mM Na-phosphate,
30 mM Na-pyrophosphate (pH 7.0), 5 mM EDTA, 0.1
mM Na3VO4, 10 mM NaF, 0.1% NP-40 – supplemented
with protease inhibitors (lysis buffer) (Roche, Germany).
The lysate was incubated on ice for 1 h, cleared by centrif-
ugation, and incubated overnight with 1 μg of α-hSIN3B,
α-ETO,  α-MTGR1,  α-MTG16 or α-MTG, and proteinA-
Sepharose (Amersham Pharmacia, Sweden). Immunopre-
cipitates were subjected to SDS-polyacrylamide gel elec-
trophoresis (PAGE) on a precast 10–20% Tris-Glycine gel
(Novex, CA, USA) and transferred to a PVDF membrane
(Amersham Pharmacia, UK). The filters were incubated
with  α-hSIN3B (SC-13145, Santa Cruz Biotechnology
Inc., USA; dilution 1:800), α-ETO, α-MTGR1, α-MTG16
or α-MTG (dilution 1:1000) and incubated with horse-
radish peroxidase-conjugated secondary antibody (Bio-
Rad, CA, USA). Rabbit pre-immune sera (PIS), rabbit pol-
yclonal antibodies to ETO homologues (α-ETO,  α-
MTGR1 and α-MTG16) and the rabbit polyclonal anti-
body α-MTG recognizing all three ETO homologues were
produced as previously described [26].
For Western blotting of placental proteins, the tissue was
homogenized in TRIZOL (Invitrogen, UK). The manufac-
turer's instructions were followed for extracting the pro-
tein. After a final wash the protein pellets were dissolved
in a buffer containing 2% CHAPS and 8 M Urea for 2 h.
The protein concentrations were measured using BCA
protein assay kit (Pierce, IL, USA). Blots were treated with
recycling kit (Chemicon, CA, USA) in order to reprobe
with α-actin (Santa Cruz Biotechnology Inc., CA, USA).
Western blots were developed using an ECL kit (Amer-
sham Pharmacia, UK).
Immunofluorescence microscopy
24 h after transfection, 0.2 × 106 COS-7 cells were redis-
tributed in a 12-well plate containing coverslips. The fol-
lowing day, the cells were washed twice with 1 mL cold
PBS, fixed with 400 μL 2% [wt/vol] paraformaldehyde
solution and incubated 30 min at room temperature.
After fixation, the cells were permeabilized in 400 μL
0.5% [vol/vol] Triton X-100 in PBS for 1 h at room tem-
perature and thereafter incubated in 300 μL blocking solu-
tion (PBS containing 0.1% bovine serum albumin [wt/
vol], 0.2% Tween 20 [vol/vol] and 5% goat serum [vol/
vol]) for 1 h at room temperature. Next, the cells were
incubated at room temperature for 1 h with the primary
antibodies – α-hSIN3B,  α-ETO,  α-MTGR1,  α-MTG16
(dilution 1:1,200) or goat primary anti-B23 (dilution
1:250; Santa Cruz Biotechnology Inc., CA, USA) – in
blocking solution. Following washing, cells were incu-
bated for 1 h with secondary antibodies – goat anti-rabbit
Alexa Fluor 488; goat anti-mouse Alexa Fluor 488, goat
anti-mouse Alexa Fluor 594, donkey anti-goat Alexa Fluor
594 (dilution 1:1,500, Eugene, OR, USA).
K562 cells were stained in suspension and attached to
poly-L-lysine-coated coverslips after staining. Briefly, 1 ×
106 cells were washed with Na-medium (5.6 mM glucose,
127 mM NaCl, 10.8 mM KCl, 2.4 mM KH2PO4, 1.6 mM
MgSO4, 10 mM HEPES, and 1.8 mM CaCl2, pH adjusted
to 7.3 with NaOH). The cells were then fixed using 1%
paraformaldehyde solution. The cells were incubated in
blocking buffer 1 (1% BSA (w/v) and 5% (v/v) goat serum
in Na-medium) for 1 h. Subsequent incubation was done
in blocking buffer 2 (Na-medium containing 1% BSA (w/
v), 0.02% Triton X-100, 0.2% Tween 20 (v/v), and 5% (v/
v) goat serum) for 30 min at room temperature. Next, cells
were treated with the primary antibodies in blocking
buffer 2 in conditions described above. Following wash-
ing, cells were incubated with the secondary antibodies
for 1 h.
After washing, cells were overlaid with ProLong Antifade
reagent with 4'-,6-Diamidino-2 Phenylindole (DAPI,
Eugene, OR, USA) to counterstain nuclei before mount-
ing. Images were recorded on a Nikon Eclipse TE300
inverted-fluorescence microscope (Nikon, Tokyo, Japan)
equipped with a Hamamatsu C4742-95 cooled CCD cam-
era, using a Plan Apochromat 100× objective and a high-
numerical-aperture oil condenser. Adobe Photoshop
(Adobe Corp., San Jose, CA, USA) was used to pseudo-
color and overlay the recorded images.
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